Pipeline

Our Pipeline

PROGRAM
CLInICAL
CANDIDATE
INDICATION
Target
LEAD ISOTOPES
DISCOVERY
Pre Clinical
Phase 1
Phase 2
Phase 3
PSMA I&T
mCRPC*, Pre-Chemo
PSMA
Lu Lutetium (177) 71
PSMA I&T
mCRPC*, Post-Chemo, combination w/ J591 (Cornell)
PSMA
Lu Lutetium (177) 71
Ac Actinium (225) 89
DOTA-TATE
Neuroendocrine Tumors (NETs)
SSTR
Lu Lutetium (177) 71
PNT6555
Solid Tumors Expressing FAP
FAP-α
Lu Lutetium (177) 71
PNT6555
Solid Tumors Expressing FAP
FAP-α
Ac Actinium (225) 89
Prostate Cancer
PSMA
Undisclosed
Targets not disclosed
PSMA
Targets not disclosed
PSMA

POINT’s CanSEEK™ has been sub-licensed from both Bach Biosciences,
which has branded the technology as pre | CISION (an Avacta trademark)

mCRPC = metatastic castatic resistant prostate cancer, PSMA = Prostate Specific Membrane Antigen, SSTR = somatostatin receptors, FAP-α = Fibrolast Activation Protein -α

Toxicity caused by off-target delivery is a longstanding concern of cancer therapies. POINT’s CanSEEK™ technology aims to minimize toxicity caused by off-target delivery by only activating a radiopharmaceuticals' targeting moiety, such as its ligand, after it has encountered FAP-α in the tumor microenvironment (TME).

Learn more

Prostate
Cancer

PNT2001
PNT2002

Prostate cancer is one of the most common types of cancer in men. While many prostate cancers grow slowly and are confined to the prostate gland, some are metastatic and spread throughout the body. 

PNT2002 is a PSMA targeted radioligand in a Phase 3 trial for an aggressive form of prostate cancer called metastatic castration-resistant prostate cancer (mCRPC).

PNT2001 is an early stage, next-generation PSMA targeted radioligand addressing toxicity concerns by focusing on increased tumor enrichment.

Learn more

Neuroendocrine tumors, also known as NETs, are neoplasms that arise from cells of the endocrine and nervous systems. They most commonly occur in the digestive tract, lungs, pancreas or lungs.

PNT2003 is a somatostatin-targeted radioligand therapy in development for the treatment of patients with somatostatin receptor-positive neuroendocrine tumors.

Learn more

A solid tumor is an abnormal clump of cells that can occur in many places including bones, muscles or organs.   

PNT2004 is an early stage Fibroblast activation protein-α (FAP-α) targeted radioligand targeted at a wide variety of solid tumor cancers.

Learn more